Cannabis Law Report

DECEMBER 2, 2021

The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. To the best of our knowledge, this is the first human clinical trial combining low doses of THC with another molecule to treat symptoms of dementia in Alzheimer’s patients.

Clinical Trials 52

Clinical Trials Data Patients THC 52

SpeedWeed

MARCH 30, 2021

A new report from cannabis market data analyst Headset shows that cannabis beverage sales continue to grow in North America and new trends indicate that the sector may be poised for gains in market share. But sales data have shown that the bold predictions have failed to pan out. Cannabis beverages actually saw a dip in the U.S.

Data 52

Data Microdosing THC Recreational 52

CannaMD

OCTOBER 7, 2019

In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. Analyzing a collection of similar research, Cannabis and Cannabinoid Research summarizes: Across these studies, on average, cannabis users consumed an additional 834?calories/day But why is THC so important?

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

JUNE 4, 2021

Paul is the author of the book Microdosing Psychedelics: A Practical Guide to Upgrade Your Life and the founder and CEO of Third Wave and co-founder of Synthesis. A THC version is expected to follow, and potentially one with psychedelic mushrooms. a leading biotech company in the hemp and cannabis industries. in/ronanlevy/. James Keim.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51